ViiV Healthcare, a healthcare company founded by Pfizer (NYSE:PFE) and GSK (NYSE:GSK), announced on Wednesday that its long-acting HIV PrEP therapy cabotegravir was found to be more acceptable to ...
ViiV Healthcare’s mission is to raise the profile of HIV across the world and create medicines to more effectively treat the disease. The company’s paramount concerns include elevating the ...
Data from the CLARITY study will provide insights on acceptability and tolerability of single-dose cabotegravir and lenacapavir long-acting injections Four-year analysis from the OPERA cohort examines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results